

**TABLE S1 Sequences of primers used for qRT-PCR in this study**

METTL14 Forward	AGAAACTGCAGGGCTTCCT
METTL14 Reverse	TCTTCTTCATATGGCAAATTTTCTT
NEAT1 Forward	GTGGCTGTTGGAGTCGGTAT
NEAT1 Reverse	TAACAAACCACGGTCCATGA
NEAT1-2 Forward	GGCCAGAGCTTTGTTGCTTC
NEAT1-2 Reverse	GGTGCGGGCACTTACTTACT
YTHDF2 Forward	TAGCCAGCTACAAGCACACCAC
YTHDF2 Reverse	CAACCGTTGCTGCAGTCTGTGT
METTL3 Forward	AAGCTGCACTTCAGACGAAT
METTL3 Reverse	GGAATCACCTCCGACACTC
$\beta$ -actin Forward	AATCGTGCGTGACATTAAGGAG
$\beta$ -actin Reverse	ACTGTGTTGGCGTACAGGTCTT

**TABLE S2 Sequences of primers used for siRNAs in this study**

METTL14-1 sense	GGACUUGGGAUGAUUUAUTT
METTL14-1 antisense	AUAAUAUCAUCCCAAGUCCTT
METTL14-2 sense	GGACUUCAUUCAUGC UAAUTT
METTL14-2 antisense	AUUAGCAUGAAUGAAGUCCTT
NEAT1-1 sense	GCCUAUCUAGUAUCUUAATT
NEAT1-1 antisense	GCCUAUCUAGUAUCUUAATT
NEAT1-2 sense	GTGGCTGTTGGAGTCGGTAT
NEAT1-2 antisense	TAACAAACCACGGTCCATGA
YTHDF2 sense	CCAUGAUUGAUGGACAGUCAGCUUU
YTHDF2 antisense	AAAGCUGACUGUCCAUAUCAUGG
Negative control sense	UUCUCCGAACGUGUCACGUTT
Negative control antisense	ACGUGACACGUUCGGAGAATT
METTL3-1 targeting sequences	GCACTGGATCTACGGAAT
METTL3-2 targeting sequences	CGACTACAGTAGCTGCCTT

**TABLE S3 Clinical characteristics analysis for 210 RCC patients according to METTL14 expression.**

Variables	Low METTL14 (n=105)	High METTL14 (n=105)	P value
Gender			0.762
Male	75	73	
Female	30	32	
Age (year)			0.555
< 60	73	69	
≥60	32	36	
Tumor size (cm)			< 0.001
< 4cm	38	72	
≥4cm	67	33	
Fuhrman grade			0.037
I/II	65	79	
III/IV	40	26	
TNM stage			0.002
I/II	67	87	
III/IV	38	18	
Metastasis			< 0.001
No	70	90	
Yes	35	15	